We selected the immortalized human osteosarcoma cell line U2OS to identify and characterize binding sites of the circadian transcription factor CLOCK/BMAL1 and its inhibitor CRY1 by chromatin immunoprecipitation and next generation sequencing (ChIP-seq). Here, CRY1 is linked to osteosarcoma.